Press coverage about Iqvia (NYSE:IQV) has been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Iqvia earned a news impact score of 0.17 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.7175548662516 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Goldman likes CRO space, sees 17% upside in IQVIA; shares up 2% (seekingalpha.com)
- Goldman Sachs Upgrades Iqvia (IQV) to “Buy” (americanbankingnews.com)
- IQVIA Holdings Inc. (IQV) projected to achieve earnings growth of 97.10% for this year (wallstreetinvestorplace.com)
- Financial Review: Iqvia (IQV) & Exelixis (EXEL) (americanbankingnews.com)
- Dennis Gillings retires from Iqvia’s board of directors (bizjournals.com)
A number of equities analysts recently weighed in on the stock. Goldman Sachs upgraded shares of Iqvia from a “neutral” rating to a “buy” rating in a research report on Friday. Argus lifted their price objective on shares of Iqvia from $110.00 to $112.00 and gave the company a “buy” rating in a research report on Monday. ValuEngine lowered shares of Iqvia from a “buy” rating to a “hold” rating in a research report on Tuesday, April 3rd. Zacks Investment Research upgraded shares of Iqvia from a “strong sell” rating to a “hold” rating in a research report on Friday, March 23rd. Finally, SunTrust Banks upgraded shares of Iqvia from a “hold” rating to a “buy” rating in a research report on Wednesday, March 7th. Eight investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $110.47.
Iqvia (NYSE:IQV) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $1.32 EPS for the quarter, missing the consensus estimate of $1.34 by ($0.02). Iqvia had a return on equity of 13.03% and a net margin of 13.44%. The business had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.14 billion. During the same quarter in the prior year, the firm earned $1.09 earnings per share. Iqvia’s quarterly revenue was up 10.7% on a year-over-year basis. research analysts expect that Iqvia will post 5.02 EPS for the current fiscal year.
In related news, Director Michael J. Evanisko sold 816 shares of the business’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $100.00, for a total value of $81,600.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider James H. Erlinger III sold 10,000 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $100.00, for a total transaction of $1,000,000.00. The disclosure for this sale can be found here. Insiders sold a total of 21,712 shares of company stock worth $2,176,034 over the last quarter. Insiders own 6.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://dakotafinancialnews.com/2018/04/14/iqvia-iqv-earns-daily-media-sentiment-rating-of-0-17.html.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.